On November 7, 2024, Abbisko Therapeutics (HKEX: 02256) today announced that it will deliver an oral presentation of updated phase 1 study results on its independently discovered oral PD-L1 inhibitor, ABSK043, in patients with advanced solid tumors at ESMO Asia Congress 2024, taking place from December 6 to 8, 2024 in Singapore.

Abbisko presentations to be held at ESMO Asia 2024:

Presentation Number: 485

Title: Updated Results of Oral PD-L1 Inhibitor ABSK043 in Advanced Solid Tumor Patients (pts) from a Phase 1 Study

Time: December 6, 10:42AM-10:52 AM

About ABSK043

ABSK043 is a novel, orally administered small molecule PD-L1 inhibitor displaying exceptional activity and high selectivity. Tumor cells can exploit immune checkpoints such as PD-1 and its ligand PD-L1 to evade immune detection and clearance, thereby suppressing or restricting T-cell responses. ABSK043 selectively binds to the PD-L1 receptor and induces its internalization from the cell surface, effectively inhibiting the PD-1/PD-L1 interaction and alleviating PD-L1-mediated suppression of T-cell activation. In several preclinical models, ABSK043 has demonstrated anti-tumor efficacy comparable to approved PD-L1 antibody drugs. While several PD-1/PD-L1 monoclonal antibodies have been approved worldwide, there are currently no approved PD-1/PD-L1 small molecule drugs. ABSK043 is currently being studied in an ongoing Phase I clinical trial for advanced solid tumors in Australia and China.